Natalie Orbach
Medical · Baltimore, MDNPI 1982761300
Payments from drug & device makers
Across 577 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$990
- AstraZeneca$822
- GSK$504
- Boehringer Ingelheim$429
- plus $4K from 40 others
What the payments were for
- Food & beverage$9,90198%
- Education$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$105
How this compares
$10,065 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $209,580 |
| MounjaroTirzepatide | 61 | $77,913 |
| JardianceEmpagliflozin | 60 | $68,451 |
| FarxigaDapagliflozin Propanediol | 59 | $60,714 |
| EliquisApixaban | 52 | $55,335 |
| TrulicityDulaglutide | 35 | $52,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $41,598 |
| JanuviaSitagliptin Phosphate | 22 | $32,777 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $26,333 |
| RybelsusSemaglutide | 11 | $19,643 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $19,053 |
| LinzessLinaclotide | 24 | $16,706 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $16,639 |
| XareltoRivaroxaban | 13 | $16,271 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $13,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,478 | $229,223180 claims |
| Lilly USA, LLCMounjaro, Trulicity | $990 | $130,55996 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $429 | $99,328101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $822 | $77,35373 claims |
| PfizerEliquis | $333 | $55,33552 claims |
| GSKTrelegy Ellipta | $504 | $41,59847 claims |
| MerckJanuvia, Janumet Xr | $195 | $40,72037 claims |
| AbbVieLinzess | $1,367 | $16,70624 claims |
| Johnson & JohnsonXarelto | $89 | $16,27113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $246 | $9,13214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.
Other medical in Baltimore
- Sarah SagorskyBaltimore$68K
- Maribeth HatalskiBaltimore$11K
- Edward MikulaBaltimore$11K
- Helen ReidlerBaltimore$10K
- Michelle DanielsBaltimore$9K
- Chana AbramsBaltimore$7K
- Joshua PertmanBaltimore$7K
- Victoria TrottStevensville$94K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.